… Standard-of-care treatment for haemophilia A or B is to maintain adequate coagulation …
for haemophilia A or B patients receiving standard half-life (SHL) vs. extended half-life (EHL) …

… for standard half-life products may be suitable. This strategy could also be used for patients
with haemophilia A … levels > 1% with prophylaxis regimens that use standard FVIII products. …

… to have a half-life prolongation of about 1.5-fold when compared to the standard half-life (SHL) …
with severe hemophilia A have been reported with EHL factors. No inhibitory antibodies …

… This article is written with the views that FVIII replacement is still the standard of care in
patients with hemophilia A [Citation23], and that FVIII products with an extended plasma half-life …

… , hemophilia joint health scores (HJHS) and quality of life (QOL) metrics. The use of EHL vs
standard half-life (SHL) products in severe hemophilia … A cohort of patients was also recruited …

… Prophylaxis with factor VIII (FVIII) is the standard treatment for patients with severe
hemophilia A (FVIII < 1%) [1]. It aims to reduce bleeding frequency and, ultimately, prevent the …

… half-life coagulation factor products (left FVIII, right FX), including the percentage reduction
of the annual infusion number compared with the standard half-life … of plasma half-life. …

… Patients now expect good efficacy, a lower treatment burden and equivalent safety when
compared with standard half-life … In patients with haemophilia A the half-life prolongation has …

… The WFH Guidelines for Management of Haemophilia … half-life (approximately 12 hours for
standard half-life FVIII [SHL-FVIII] and 18 hours for standard half-life FIX [SHL-FIX]), standard …

… The mean age was 28.8 (standard deviation (SD) 11.8) years. Factor VIII halflife ranged from
… We found that age was an important determinant of FVIII halflife. In contrast, Vlot et al. did …